Burnett John R
Department of Core Clinical Pathology & Biochemistry, Royal Perth Hospital and School of Surgery and Pathology, University of Western Australia, Wellington Street, GPO Box X2213, Perth, Western Australia 6847, Australia.
Curr Opin Investig Drugs. 2003 Mar;4(3):347-51.
Eflucimibe is an acyl coenzyme A:cholesterol acyltransferase inhibitor under development by Pierre Fabre SA and Eli Lilly & Co for the potential treatment of hypercholesterolemia and atherosclerosis. Phase II clinical trials commenced during 2002.
依氟米贝是一种酰基辅酶A：胆固醇酰基转移酶抑制剂，由皮尔法伯制药公司（Pierre Fabre SA）和礼来公司（Eli Lilly & Co）联合开发，用于潜在治疗高胆固醇血症和动脉粥样硬化。2002年开始进行II期临床试验。
